Organization Profile

You just read:

Spero Therapeutics Licenses Dihydrofolate Reductase Inhibitors from Promiliad Biopharma to Enhance Anti-Infective Pipeline

News provided by

Spero Therapeutics

Jan 07, 2016, 09:00 ET